BioCentury | Mar 16, 2017
Financial News

Aerpio raises $40M ahead of planned OTC listing

...The reverse merger combined Aerpio's former incarnation, Aerpio Therapeutics Inc. , with public shell company Zeta Acquisition...
BioCentury | May 4, 2015
Company News

University of Michigan, Kura Oncology deal

...Therapy Acceleration Program (TAP). Earlier this year, Kura disclosed the program after it reverse-merged with Zeta Acquisition Corp. III...
BioCentury | Mar 16, 2015
Financial News

Kura Oncology completes venture financing

...bridge funding, which converted into common stock. In conjunction with the offering, Kura reversed-merged with Zeta Acquisition Corp. III...
BioCentury | Mar 16, 2015
Company News

Zeta Acquisition, Kura Oncology deal

...Kura Oncology completed its reverse-merger with shell company Zeta Acquisition Corp. III. The non-trading public company will seek to...
...New Brunswick, N.J.) to develop and commercialize tipifarnib, a farnesyl transferase inhibitor, to treat cancer. Zeta Acquisition Corp. III...
BioCentury | Mar 13, 2015
Company News

Kura licenses J&J's tipifarnib, raises $60M

...from the Janssen Pharmaceutica NV unit of Johnson & Johnson (NYSE:JNJ), reverse-merged with shell company Zeta Acquisition Corp. III...
Items per page:
1 - 5 of 5
BioCentury | Mar 16, 2017
Financial News

Aerpio raises $40M ahead of planned OTC listing

...The reverse merger combined Aerpio's former incarnation, Aerpio Therapeutics Inc. , with public shell company Zeta Acquisition...
BioCentury | May 4, 2015
Company News

University of Michigan, Kura Oncology deal

...Therapy Acceleration Program (TAP). Earlier this year, Kura disclosed the program after it reverse-merged with Zeta Acquisition Corp. III...
BioCentury | Mar 16, 2015
Financial News

Kura Oncology completes venture financing

...bridge funding, which converted into common stock. In conjunction with the offering, Kura reversed-merged with Zeta Acquisition Corp. III...
BioCentury | Mar 16, 2015
Company News

Zeta Acquisition, Kura Oncology deal

...Kura Oncology completed its reverse-merger with shell company Zeta Acquisition Corp. III. The non-trading public company will seek to...
...New Brunswick, N.J.) to develop and commercialize tipifarnib, a farnesyl transferase inhibitor, to treat cancer. Zeta Acquisition Corp. III...
BioCentury | Mar 13, 2015
Company News

Kura licenses J&J's tipifarnib, raises $60M

...from the Janssen Pharmaceutica NV unit of Johnson & Johnson (NYSE:JNJ), reverse-merged with shell company Zeta Acquisition Corp. III...
Items per page:
1 - 5 of 5